Which has stronger valuation & earnings, KLRA or APGE?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A Apogee Therapeutics N/A N/A -$255.84M -$4.34 N/A

Is KLRA or APGE more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Apogee Therapeutics N/A -29.88% -28.08%

Does the media prefer KLRA or APGE?

In the previous week, Apogee Therapeutics had 8 more articles in the media than Kailera Therapeutics. MarketBeat recorded 12 mentions for Apogee Therapeutics and 4 mentions for Kailera Therapeutics. Apogee Therapeutics' average media sentiment score of 1.39 beat Kailera Therapeutics' score of -0.09 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Apogee Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TGTX or KLRA?

In the previous week, TG Therapeutics had 9 more articles in the media than Kailera Therapeutics. MarketBeat recorded 13 mentions for TG Therapeutics and 4 mentions for Kailera Therapeutics. TG Therapeutics' average media sentiment score of 0.90 beat Kailera Therapeutics' score of -0.09 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is KLRA or IBRX more profitable?

Kailera Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A ImmunityBio -598.55% N/A -51.65%

Does the media favor KLRA or IBRX?

In the previous week, ImmunityBio had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for ImmunityBio and 4 mentions for Kailera Therapeutics. ImmunityBio's average media sentiment score of 0.89 beat Kailera Therapeutics' score of -0.09 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ImmunityBio 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ALKS or KLRA?

Alkermes has higher revenue and earnings than Kailera Therapeutics. Kailera Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.67B 4.80 $241.66M $0.38 125.58 Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Does the media prefer ALKS or KLRA?

In the previous week, Alkermes had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for Alkermes and 4 mentions for Kailera Therapeutics. Alkermes' average media sentiment score of 0.46 beat Kailera Therapeutics' score of -0.09 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor KLRA or RYTM?

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Kailera Therapeutics. MarketBeat recorded 9 mentions for Rhythm Pharmaceuticals and 4 mentions for Kailera Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Kailera Therapeutics' score of -0.09 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kailera Therapeutics (KLRA) Competitors

$15.85 -0.56 (-3.41%)

As of 09/2/2026 04:00 PM Eastern

Compare

KLRA vs. APGE, TGTX, IBRX, ALKS, and RYTM

Should you buy Kailera Therapeutics stock or one of its competitors? Kailera Therapeutics's main competitors and comparable companies include Apogee Therapeutics (APGE), TG Therapeutics (TGTX), ImmunityBio (IBRX), Alkermes (ALKS), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kailera Therapeutics compare to Apogee Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Kailera Therapeutics presently has a consensus price target of $42.75, suggesting a potential upside of 169.72%. Apogee Therapeutics has a consensus price target of $126.77, suggesting a potential downside of 6.14%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Kailera Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

In the previous week, Apogee Therapeutics had 8 more articles in the media than Kailera Therapeutics. MarketBeat recorded 12 mentions for Apogee Therapeutics and 4 mentions for Kailera Therapeutics. Apogee Therapeutics' average media sentiment score of 1.39 beat Kailera Therapeutics' score of -0.09 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Apogee Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Apogee Therapeutics	N/A	-29.88%	-28.08%

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Summary

Kailera Therapeutics beats Apogee Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Kailera Therapeutics compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

TG Therapeutics has higher revenue and earnings than Kailera Therapeutics. Kailera Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	14.13	$447.18M	$2.74	20.77
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

In the previous week, TG Therapeutics had 9 more articles in the media than Kailera Therapeutics. MarketBeat recorded 13 mentions for TG Therapeutics and 4 mentions for Kailera Therapeutics. TG Therapeutics' average media sentiment score of 0.90 beat Kailera Therapeutics' score of -0.09 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

TG Therapeutics has a net margin of 55.22% compared to Kailera Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Kailera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Kailera Therapeutics	N/A	N/A	N/A

58.6% of TG Therapeutics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TG Therapeutics presently has a consensus target price of $63.00, suggesting a potential upside of 10.72%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 169.72%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

TG Therapeutics beats Kailera Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Kailera Therapeutics compare to ImmunityBio?

Kailera Therapeutics (NASDAQ:KLRA) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Kailera Therapeutics presently has a consensus target price of $42.75, suggesting a potential upside of 169.72%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 78.62%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kailera Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Kailera Therapeutics has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
ImmunityBio	$113.29M	74.37	-$351.40M	-$0.97	N/A

In the previous week, ImmunityBio had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for ImmunityBio and 4 mentions for Kailera Therapeutics. ImmunityBio's average media sentiment score of 0.89 beat Kailera Therapeutics' score of -0.09 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ImmunityBio	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
ImmunityBio	-598.55%	N/A	-51.65%

8.6% of ImmunityBio shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Kailera Therapeutics and ImmunityBio tied by winning 7 of the 14 factors compared between the two stocks.

How does Kailera Therapeutics compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

95.2% of Alkermes shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alkermes has a net margin of 3.96% compared to Kailera Therapeutics' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Kailera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Kailera Therapeutics	N/A	N/A	N/A

Alkermes presently has a consensus price target of $54.56, suggesting a potential upside of 14.34%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 169.72%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Alkermes has higher revenue and earnings than Kailera Therapeutics. Kailera Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.67B	4.80	$241.66M	$0.38	125.58
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

In the previous week, Alkermes had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for Alkermes and 4 mentions for Kailera Therapeutics. Alkermes' average media sentiment score of 0.46 beat Kailera Therapeutics' score of -0.09 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Alkermes beats Kailera Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Kailera Therapeutics compare to Rhythm Pharmaceuticals?

Kailera Therapeutics (NASDAQ:KLRA) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Kailera Therapeutics. MarketBeat recorded 9 mentions for Rhythm Pharmaceuticals and 4 mentions for Kailera Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Kailera Therapeutics' score of -0.09 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics presently has a consensus price target of $42.75, indicating a potential upside of 169.72%. Rhythm Pharmaceuticals has a consensus price target of $141.12, indicating a potential upside of 33.86%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Kailera Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

Kailera Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Kailera Therapeutics' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Kailera Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Rhythm Pharmaceuticals	$189.76M	38.07	-$196.54M	-$3.11	N/A

Summary

Kailera Therapeutics beats Rhythm Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Kailera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRA vs. The Competition

Export

Metric	Kailera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.13B	$3.99B	$7.21B	$12.67B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	0.00	12.25	272.66	25.23
Price / Sales	N/A	1,407.15	635.76	104.55
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	1.84	16.14	12.83	6.10
Net Income	-$148.96M	-$22.72M	$3.47B	$348.86M
7 Day Performance	-14.46%	-1.23%	-0.12%	-1.90%
1 Month Performance	-8.49%	11.26%	6.74%	1.96%
1 Year Performance	N/A	53.10%	25.09%	15.30%

Kailera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRA Kailera Therapeutics	2.2643 of 5 stars	$15.85 -3.4%	$42.75 +169.7%	N/A	$2.13B	N/A	N/A	145
APGE Apogee Therapeutics	1.5835 of 5 stars	$134.75 flat	$124.43 -7.7%	+256.8%	$8.38B	N/A	N/A	91	Positive News
TGTX TG Therapeutics	2.9571 of 5 stars	$54.27 +7.3%	$63.00 +16.1%	+91.4%	$8.31B	$616.29M	19.81	290	Analyst Forecast High Trading Volume
IBRX ImmunityBio	2.1616 of 5 stars	$7.79 -0.6%	$14.20 +82.3%	+234.0%	$8.26B	$113.29M	N/A	590
ALKS Alkermes	2.1346 of 5 stars	$48.33 +0.6%	$54.56 +12.9%	+62.3%	$8.11B	$1.48B	127.19	2,050	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRA) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kailera Therapeutics (KLRA) Competitors

KLRA vs. APGE, TGTX, IBRX, ALKS, and RYTM

How does Kailera Therapeutics compare to Apogee Therapeutics?

Summary

How does Kailera Therapeutics compare to TG Therapeutics?

Summary

How does Kailera Therapeutics compare to ImmunityBio?

Summary

How does Kailera Therapeutics compare to Alkermes?

Summary

How does Kailera Therapeutics compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kailera Therapeutics (KLRA) Competitors

KLRA vs. APGE, TGTX, IBRX, ALKS, and RYTM

How does Kailera Therapeutics compare to Apogee Therapeutics?

Do analysts recommend KLRA or APGE?

Does the media prefer KLRA or APGE?

Is KLRA or APGE more profitable?

Do insiders and institutionals hold more shares of KLRA or APGE?

Which has stronger valuation & earnings, KLRA or APGE?

Summary

How does Kailera Therapeutics compare to TG Therapeutics?

Which has preferable valuation & earnings, TGTX or KLRA?

Does the media favor TGTX or KLRA?

Is TGTX or KLRA more profitable?

Do insiders & institutionals have more ownership in TGTX or KLRA?

Do analysts prefer TGTX or KLRA?

Summary

How does Kailera Therapeutics compare to ImmunityBio?

Do analysts recommend KLRA or IBRX?

Which has preferable earnings and valuation, KLRA or IBRX?

Does the media favor KLRA or IBRX?

Is KLRA or IBRX more profitable?

Do institutionals & insiders hold more shares of KLRA or IBRX?

Summary

How does Kailera Therapeutics compare to Alkermes?

Do institutionals and insiders have more ownership in ALKS or KLRA?

Is ALKS or KLRA more profitable?

Do analysts recommend ALKS or KLRA?

Which has higher earnings and valuation, ALKS or KLRA?

Does the media prefer ALKS or KLRA?

Summary

How does Kailera Therapeutics compare to Rhythm Pharmaceuticals?

Does the media favor KLRA or RYTM?

Do analysts recommend KLRA or RYTM?

Is KLRA or RYTM more profitable?

Which has better valuation and earnings, KLRA or RYTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools